Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178080286> ?p ?o ?g. }
- W3178080286 endingPage "1295" @default.
- W3178080286 startingPage "1280" @default.
- W3178080286 abstract "Abstract Background Ghrelin may ameliorate cancer cachexia (CC) by preventing anorexia, muscle, and fat loss. However, the mechanisms mediating these effects are not fully understood. This study characterizes the pathways involved in muscle mass and strength loss in the Lewis lung carcinoma (LLC)‐induced cachexia model, and the effects of ghrelin in mice with or without its only known receptor: the growth hormone secretagogue receptor‐1a ((GHSR‐1a), Ghsr +/+ and Ghsr −/− ). Methods Five to 7‐month‐old male C57BL/6J Ghsr +/+ and Ghsr −/− mice were inoculated with 1 × 10 6 heat‐killed (HK) or live LLC cells (tumour implantation, TI). When tumours were palpable (7 days after TI), tumour‐bearing mice were injected with vehicle (T + V) or ghrelin twice/day for 14 days (T + G, 0.8 mg/kg), while HK‐treated mice were given vehicle (HK + V). Body weight and grip strength were evaluated before TI and at termination (21 days after TI). Hindlimb muscles were collected for analysis. Results Less pronounced body weight (BW) loss (87.70 ± 0.98% vs. 83.92 ± 1.23%, percentage of baseline BW in tumour‐bearing Ghsr +/+ vs. Ghsr −/− , P = 0.008), and lower upregulation of ubiquitin‐proteasome system (UPS, MuRF1/ Trim63 , 5.71 ± 1.53‐fold vs. 9.22 ± 1.94‐fold‐change from Ghsr +/+ HK + V in tumour‐bearing Ghsr +/+ vs. Ghsr ‐/‐ , P = 0.036) and autophagy markers ( Becn1 , Atg5 , Atg7 , tumour‐bearing Ghsr +/+ < Ghsr −/− , all P < 0.02) were found in T + V Ghsr +/+ vs. Ghsr −/− mice. Ghrelin attenuated LLC‐induced UPS marker upregulation in both genotypes, [ Trim63 was decreased from 5.71 ± 1.53‐fold to 1.96 ± 0.47‐fold in Ghsr +/+ (T + V vs. T + G: P = 0.032) and 9.22 ± 1.94‐fold to 4.72 ± 1.06‐fold in Ghsr −/− (T + V vs. T + G: P = 0.008)]. Only in Ghsr +/+ mice ghrelin ameliorated LLC‐induced grip strength loss [improved from 89.24 ± 3.48% to 97.80 ± 2.31% of baseline (T + V vs. T + G: P = 0.042)], mitophagy markers [ Bnip3 was decreased from 2.28 ± 0.56 to 1.38 ± 0.14‐fold (T + V vs. T + G: P ≤ 0.05)], and impaired mitochondrial respiration [State 3u improved from 698.23 ± 73.96 to 934.37 ± 95.21 pmol/min (T + V vs. T + G: P ≤ 0.05)], whereas these markers were not improved by ghrelin Ghsr −/− . Compared with Ghsr +/+ , Ghsr −/− tumour‐bearing mice also showed decreased response to ghrelin in BW [T + G‐treated Ghsr +/+ vs. Ghsr −/− : 91.75 ± 1.05% vs. 86.18 ± 1.13% of baseline BW, P < 0.001)], gastrocnemius (T + G‐treated Ghsr +/+ vs. Ghsr −/− : 96.9 ± 2.08% vs. 88.15 ± 1.78% of Ghsr +/+ HK + V, P < 0.001) and quadriceps muscle mass (T + G‐treated Ghsr +/+ vs. Ghsr −/− : 96.12 ± 2.31% vs. 88.36 ± 1.94% of Ghsr +/+ HK + V, P = 0.01), and gastrocnemius type IIA (T + G‐treated Ghsr +/+ vs. Ghsr −/− : 1250.49 ± 31.72 vs. 1017.62 ± 70.99 μm 2 , P = 0.027) and IIB fibre cross‐sectional area (T + G‐treated Ghsr +/+ vs. Ghsr −/− : 2496.48 ± 116.88 vs. 2183.04 ± 103.43 μm 2 , P = 0.024). Conclusions Growth hormone secretagogue receptor‐1a mediates ghrelin's effects on attenuating LLC‐induced weakness but not muscle mass loss by modulating the autophagy‐lysosome pathway, mitophagy, and mitochondrial respiration." @default.
- W3178080286 created "2021-07-19" @default.
- W3178080286 creator A5018137583 @default.
- W3178080286 creator A5037736808 @default.
- W3178080286 creator A5039951446 @default.
- W3178080286 creator A5043243789 @default.
- W3178080286 creator A5061811930 @default.
- W3178080286 creator A5062407671 @default.
- W3178080286 creator A5064975488 @default.
- W3178080286 creator A5065972651 @default.
- W3178080286 creator A5066445273 @default.
- W3178080286 creator A5068954028 @default.
- W3178080286 creator A5084714265 @default.
- W3178080286 creator A5089366867 @default.
- W3178080286 creator A5089743220 @default.
- W3178080286 date "2021-07-15" @default.
- W3178080286 modified "2023-10-14" @default.
- W3178080286 title "Growth hormone secretagogue receptor‐1a mediates ghrelin's effects on attenuating tumour‐induced loss of muscle strength but not muscle mass" @default.
- W3178080286 cites W126188432 @default.
- W3178080286 cites W1488497469 @default.
- W3178080286 cites W1541314725 @default.
- W3178080286 cites W1563717553 @default.
- W3178080286 cites W1581921270 @default.
- W3178080286 cites W1601262489 @default.
- W3178080286 cites W1654990989 @default.
- W3178080286 cites W1830507501 @default.
- W3178080286 cites W1850103453 @default.
- W3178080286 cites W1987892987 @default.
- W3178080286 cites W1999532278 @default.
- W3178080286 cites W2002128555 @default.
- W3178080286 cites W2011387037 @default.
- W3178080286 cites W2018422556 @default.
- W3178080286 cites W2026358146 @default.
- W3178080286 cites W2026788188 @default.
- W3178080286 cites W2034127653 @default.
- W3178080286 cites W2035304443 @default.
- W3178080286 cites W2044928655 @default.
- W3178080286 cites W2048494900 @default.
- W3178080286 cites W2053855527 @default.
- W3178080286 cites W2057741310 @default.
- W3178080286 cites W2060792177 @default.
- W3178080286 cites W2083560906 @default.
- W3178080286 cites W2084515449 @default.
- W3178080286 cites W2094805002 @default.
- W3178080286 cites W2100688137 @default.
- W3178080286 cites W2104551901 @default.
- W3178080286 cites W2107960666 @default.
- W3178080286 cites W2116663463 @default.
- W3178080286 cites W2118708400 @default.
- W3178080286 cites W2120348861 @default.
- W3178080286 cites W2122289503 @default.
- W3178080286 cites W2127440157 @default.
- W3178080286 cites W2128677681 @default.
- W3178080286 cites W2130053803 @default.
- W3178080286 cites W2130246533 @default.
- W3178080286 cites W2131441161 @default.
- W3178080286 cites W2144489715 @default.
- W3178080286 cites W2145280166 @default.
- W3178080286 cites W2158534725 @default.
- W3178080286 cites W2159664830 @default.
- W3178080286 cites W2159796957 @default.
- W3178080286 cites W2163865122 @default.
- W3178080286 cites W2167033587 @default.
- W3178080286 cites W2167512318 @default.
- W3178080286 cites W2169512179 @default.
- W3178080286 cites W2175296021 @default.
- W3178080286 cites W2175926612 @default.
- W3178080286 cites W2177308292 @default.
- W3178080286 cites W2253924460 @default.
- W3178080286 cites W2278001291 @default.
- W3178080286 cites W2279428213 @default.
- W3178080286 cites W2345927750 @default.
- W3178080286 cites W2462761346 @default.
- W3178080286 cites W2504380105 @default.
- W3178080286 cites W2515145834 @default.
- W3178080286 cites W2515668542 @default.
- W3178080286 cites W2534399581 @default.
- W3178080286 cites W2549027334 @default.
- W3178080286 cites W2556459139 @default.
- W3178080286 cites W2575725705 @default.
- W3178080286 cites W2594925179 @default.
- W3178080286 cites W2620889633 @default.
- W3178080286 cites W2734836322 @default.
- W3178080286 cites W2747686805 @default.
- W3178080286 cites W2750286828 @default.
- W3178080286 cites W2759460919 @default.
- W3178080286 cites W2761629122 @default.
- W3178080286 cites W2765244546 @default.
- W3178080286 cites W2766816365 @default.
- W3178080286 cites W2771156760 @default.
- W3178080286 cites W2784374589 @default.
- W3178080286 cites W2802706983 @default.
- W3178080286 cites W2888425026 @default.
- W3178080286 cites W2899954777 @default.
- W3178080286 cites W2910535306 @default.
- W3178080286 cites W2947659393 @default.
- W3178080286 cites W2963741701 @default.
- W3178080286 cites W2970862723 @default.